M&A / Deals GSK bolts on siRNA drug from China’s SiranBio in $1bn deal PharmaphorumGSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.Read full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaphorum GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio. Read full story Post navigation Previous: CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineNext: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026